Singapore-based cancer diagnostics technology developer Mirxes has secured $77m in a series C round led by CR-CP Life Science Fund, a partnership between conglomerates China Resources Group and Charoen Pokphand Group.
The round also featured Rock Springs Capital, EDBI, CCBI and Keytone Ventures. It took the company’s overall funding to $120m since it was founded in 2014, Mirxes said.
Spun out of Singapore’s public research and development hub Agency for Science, Technology, and Research, Mirxes is developing RNA-based tests designed for early diagnosis of diseases including colorectal, breast, gastric, lung, liver, ovarian and thyroid cancers.
Lihan Zhou, co-founder and CEO of Mirxes, said: “With this fresh funding, Mirxes will bring forward our plans to deliver a comprehensive portfolio of non-invasive screening tests for early detection of six major cancers, and to expand the use of our platform RNA technology for cardiovascular, metabolic and infectious diseases research and diagnostics globally.”
Venture capital firm Venturecraft Group had provided an undisclosed amount of funding for Mirxes in 2016 before merging with it two years later to form a larger company then called Ark.
